A Phase II Trial of Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Localized Prostate Cancer
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of undetectable PSA (<0.1 ng/ml)
Undetectable PSA at 1 year from treatment initiation
1 year
No
Bridget Koontz, MD
Principal Investigator
Duke University
United States: Institutional Review Board
Pro00044071
NCT01717053
September 2013
September 2016
Name | Location |
---|---|
Durham Regional Hospital | Durham, North Carolina 27704-2763 |
Duke University Medical Center | Durham, North Carolina 27710 |